Active substance
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| ELIGARD 22.5 MG POWDER FOR SOLUTION FOR INJECTION | 22.5 mg | Powder and solvent for solution for injection · Subcutaneous use | 1 Vial | SAR 796.80 | NCE · Prescription | ASTELLAS PHARMA | Valid |
| ELIGARD 45 MG POWDER FOR SOLUTION FOR INJECTION | 45 mg | Powder and solvent for solution for injection · Subcutaneous use | 1 Vial | SAR 1750.85 | NCE · Prescription | ASTELLAS PHARMA | Valid |
| ELIGARD 7.5 MG POWDER FOR SOLUTION FOR INJECTION | 7.5 mg | Powder and solvent for solution for injection · Subcutaneous use | 1 Vial | SAR 313.90 | NCE · Prescription | ASTELLAS PHARMA | Valid |
| LUPRON DEPOT 3.75MG-VIAL | 3.75 mg | Powder and solvent for suspension for injection · Subcutaneous use | 1 Pre-filled syringe | SAR 423.90 | NCE · Prescription | Abbvie BV. | Valid |
| LUPRON DEPOT 7.5MG -VIAL | 7.5 mg | Powder and solvent for suspension for injection · Subcutaneous use | 1 Vial | SAR 574.75 | NCE · Prescription | ABBVIE Inc. | Withdrawn by MAH · Not Marketed |
ENDOMETRIOSIS; PROSTATE CANCER
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| LUPRON DEPOT | 7.5MG | injectable · injection | ABBVIE ENDOCRINE INC | Prescription | 26 Jan 1989 |
| LUPRON DEPOT | 3.75MG | injectable · injection | ABBVIE ENDOCRINE INC | Prescription | 22 Oct 1990 |
| LUPRON DEPOT-PED KIT | 7.5MG; 11.25MG; 15MG; 30MG; 45MG | powder · intramuscular | ABBVIE ENDOCRINE INC | Prescription | 16 Apr 1993 |
| LUPRON DEPOT | 3.75MG | injectable · injection | ABBVIE ENDOCRINE INC | Prescription | 30 Mar 1995 |
| LUPRON DEPOT | 22.5MG; 30MG; 45MG | injectable · injection | ABBVIE ENDOCRINE INC | Prescription | 22 Dec 1995 |
| LUPRON DEPOT | 11.25MG | injectable · injection | ABBVIE ENDOCRINE INC | Prescription | 7 Mar 1997 |
| LEUPROLIDE ACETATE | 14MG/2.8ML (1MG/0.2ML) | solution · subcutaneous | SANDOZ | Prescription | 4 Aug 1998 |
| LEUPROLIDE ACETATE | 14MG/2.8ML (1MG/0.2ML) | solution · subcutaneous | MEITHEAL | Prescription | 25 Oct 2000 |
| ELIGARD KIT | 7.5MG | powder · subcutaneous | TOLMAR | Prescription | 23 Jan 2002 |
| ELIGARD KIT | 22.5MG | powder · subcutaneous | TOLMAR | Prescription | 24 Jul 2002 |
| ELIGARD KIT | 30MG | powder · subcutaneous | TOLMAR | Prescription | 13 Feb 2003 |
| ELIGARD KIT | 45MG | powder · subcutaneous | TOLMAR | Prescription | 14 Dec 2004 |
| LEUPROLIDE ACETATE | 14MG/2.8ML (1MG/0.2ML) | solution · subcutaneous | SUN PHARM | Prescription | 9 Mar 2009 |
| LEUPROLIDE ACETATE FOR DEPOT SUSPENSION | 22.5MG/VIAL | for suspension · intramuscular | INVAGEN PHARMS | Prescription | 28 Aug 2018 |
| FENSOLVI KIT | 45MG | powder · subcutaneous | TOLMAR | Prescription | 1 May 2020 |
| CAMCEVI KIT | EQ 42MG BASE | emulsion · subcutaneous | ACCORD | Prescription | 25 May 2021 |
| LEUPROLIDE ACETATE | 14MG/2.8ML (1MG/0.2ML) | solution · subcutaneous | SOMERSET THERAPS LLC | Prescription | 13 Aug 2021 |
| LEUPROLIDE ACETATE | 14MG/2.8ML (1MG/0.2ML) | solution · subcutaneous | EUGIA PHARMA | Prescription | 6 Jun 2022 |
| LEUPROLIDE ACETATE | 14MG/2.8ML (1MG/0.2ML) | solution · subcutaneous | AMNEAL | Prescription | 28 Oct 2022 |
| LEUPROLIDE ACETATE | 14MG/2.8ML (1MG/0.2ML) | solution · subcutaneous | UBI | Prescription | 17 Oct 2024 |
| CAMCEVI ETM | EQ 21MG BASE | emulsion · subcutaneous | ACCORD | Prescription | 25 Aug 2025 |
| LEUPROLIDE ACETATE | 14MG/2.8ML (1MG/0.2ML) | solution · subcutaneous | ZYDUS PHARMS | Prescription | 13 Nov 2025 |
| LUPRON | 14MG/2.8ML (1MG/0.2ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | solution · subcutaneous | ABBVIE ENDOCRINE INC | Discontinued | 9 Apr 1985 |
| LUPRON DEPOT | 3.75MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | injectable · injection | ABBVIE ENDOCRINE INC | Discontinued | 22 Oct 1990 |
| LUPRON DEPOT-PED KIT | 3.75MG,7.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; 7.5MG,7.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | powder · intramuscular | ABBVIE ENDOCRINE INC | Discontinued | 16 Apr 1993 |
4 more — full table
Camcevi is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy.
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| ELIGARD | 02248239 | 7.5 MG / SYR | POWDER FOR SUSPENSION (SUSTAINED-RELEASE · SUBCUTANEOUS | TOLMAR INTERNATIONAL LTD. |
| ELIGARD | 02248240 | 22.5 MG / SYR | POWDER FOR SUSPENSION (SUSTAINED-RELEASE · SUBCUTANEOUS | TOLMAR INTERNATIONAL LTD. |
| ELIGARD | 02248999 | 30 MG / SYR | POWDER FOR SUSPENSION (SUSTAINED-RELEASE · SUBCUTANEOUS | TOLMAR INTERNATIONAL LTD. |
| ELIGARD | 02268892 | 45 MG / SYR | POWDER FOR SUSPENSION (SUSTAINED-RELEASE · SUBCUTANEOUS | TOLMAR INTERNATIONAL LTD. |
| LUPRON DEPOT | 00836273 | 7.5 MG / SYR | POWDER FOR SUSPENSION (SUSTAINED-RELEASE · INTRAMUSCULAR | ABBVIE CORPORATION |
| LUPRON DEPOT | 00884502 | 3.75 MG / SYR | POWDER FOR SUSPENSION (SUSTAINED-RELEASE · INTRAMUSCULAR | ABBVIE CORPORATION |
| LUPRON DEPOT | 02230248 | 22.5 MG / SYR | POWDER FOR SUSPENSION (SUSTAINED-RELEASE · INTRAMUSCULAR | ABBVIE CORPORATION |
| LUPRON DEPOT | 02239833 | 30 MG / SYR | POWDER FOR SUSPENSION (SUSTAINED-RELEASE · INTRAMUSCULAR | ABBVIE CORPORATION |
| LUPRON DEPOT | 02239834 | 11.25 MG / SYR | POWDER FOR SUSPENSION (SUSTAINED-RELEASE · INTRAMUSCULAR | ABBVIE CORPORATION |
| LUPRON DEPOT | 02562855 | 45 MG / SYR | POWDER FOR SUSPENSION (SUSTAINED-RELEASE · INTRAMUSCULAR | ABBVIE CORPORATION |
| ZEULIDE DEPOT | 02429977 | 3.75 MG / VIAL | KIT; POWDER FOR SUSPENSION (SUSTAINED-RELEASE · INTRAMUSCULAR | VERITY PHARMACEUTICALS INC. |
| ZEULIDE DEPOT | 02462699 | 22.5 MG / VIAL | POWDER FOR SUSPENSION (SUSTAINED-RELEASE; KIT · INTRAMUSCULAR | VERITY PHARMACEUTICALS INC. |
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | LEUPROLIDE 2WK 14 MG/2.8 ML KT | $197.606 | per EA | 3 Jun 2026 |
| US NADAC | LUPRON DEPOT 11.25 MG 3MO KIT | $5437.39667 | per EA | 23 Sep 2026 |
| US NADAC | LUPRON DEPOT 3.75 MG KIT | $1822.07714 | per EA | 23 Sep 2026 |
| US NADAC | LUPRON DEPOT 7.5 MG 1 MONTH KT | $2174.1678 | per EA | 22 Jul 2026 |
| NHS Drug Tariff | Leuprorelin 1.88mg powder and solvent for prolonged-release suspension for injection pre-filled syringes | £60.00 | 1 pre-filled disposable injection | 1 Oct 2026 |
| NHS Drug Tariff | Leuprorelin 11.25mg implant pre-filled syringes | £75.00 | 1 pre-filled disposable injection | 1 Oct 2026 |
| NHS Drug Tariff | Leuprorelin 11.25mg powder and solvent for prolonged-release suspension for injection pre-filled syringes | £225.72 | 1 pre-filled disposable injection | 1 Oct 2026 |
| NHS Drug Tariff | Leuprorelin 3.75mg powder and solvent for prolonged-release suspension for injection pre-filled syringes | £75.24 | 1 pre-filled disposable injection | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.